下肢血液透析血管通路结局的系统评价与荟萃分析
该系统评价与荟萃分析纳入45项研究(47篇报告),评估下肢血液透析血管通路的通畅性、并发症与死亡率。汇总结果显示,一期通畅率从6个月的69%降至24个月的35%,二期通畅率相应为80%和67%。12个月时,自体动静脉内瘘/股静脉转位(AVF/FVT)的一期和二期通畅率均高于人工血管移植物,且感染率更低。
要点
- 下肢透析通路是上肢通路失败后的可行挽救选择,二期通畅率优于一期通畅率。
- 12个月时自体AVF/FVT一期通畅率79%,高于人工血管移植物的53%。
- 人工血管移植物感染率19%,高于自体AVF/FVT的7%。
核心结论
- 下肢血液透析通路是可行的挽救选择,二期通畅率得以维持,但无干预通畅率随时间下降。
- 自体AVF/FVT可能提供更优的12个月通畅率和更低的感染风险,但异质性和观察性证据需谨慎解读。
研究设计与样本
- 系统评价与荟萃分析,检索PubMed、Scopus、Web of Science和MEDLINE从建库至2026年4月30日。
- 纳入45项研究(47篇报告),对象为接受手术建立下肢血液透析通路的成人。
- 采用随机效应比例荟萃分析,logit转换和逆方差加权,按随访时长和通路类型分层。
主要发现
- 一期通畅率从6个月的69%(95%CI 45%-86%;I²=85.5%)降至12个月的62%(95%CI 53%-70%;I²=85.0%)和24个月的35%(95%CI 22%-43%;I²=86.1%)。
- 二期通畅率6个月为80%(95%CI 63%-90%;I²=78.6%),12个月为81%(95%CI 75%-87%;I²=82.5%),24个月为67%(95%CI 51%-80%;I²=90.0%)。
临床怎么用
- 对于上肢血管通路耗竭或解剖不适合的患者,可考虑下肢血液透析通路作为挽救选项。
- 优先选择自体AVF/FVT可能带来更优的12个月通畅率和更低的感染风险。
- 需权衡下肢通路较高的血栓形成、感染和缺血风险,个体化决策。
局限性
- 纳入研究为观察性证据,存在异质性(I²普遍较高)。
- 结果需谨慎解读,可能与研究间差异和随访时长分层有关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lower-extremity vascular access is used when conventional upper-extremity options for hemodialysis (HD) have failed or are anatomically unsuitable; however, its durability and complication profile remain uncertain. This systematic review and meta-analysis evaluated patency, graft survival, complications, mortality, and differences by access class after lower-extremity HD access creation. METHODS: PubMed, Scopus, Web of Science, and MEDLINE were searched from inception to April 30, 2026. Studies of surgically created lower-extremity HD access in adults were included. Random-effects proportional meta-analyses were performed using logit transformation and inverse-variance weighting. Outcomes were stratified by follow-up duration and access class where feasible. RESULTS: Forty-five studies, corresponding to 47 reports, were included. Pooled primary patency declined from 69% at 6 months [95% confidence interval (CI), 45%-86%; I2 = 85.5%] to 62% at 12 months (95% CI, 53%-70%; I2 = 85.0%), and 35% at 24 months (95% CI, 22%-43%; I2 = 86.1%). Secondary patency was higher, with pooled estimates of 80% at 6 months (95% CI, 63%-90%; I2 = 78.6%), 81% at 12 months (95% CI, 75%-87%; I2 = 82.5%), and 67% at 24 months (95% CI, 51%-80%; I2 = 90.0%). At 12 months, autogenous arteriovenous fistula (AVF)/femoral vein transposition (FVT) had higher primary patency than prosthetic arteriovenous graft access (79% vs 53%; subgroup P = .0016), supported by direct comparison (risk ratio, 1.23; 95% CI, 1.08-1.39; P = .0011). Secondary patency was also higher with AVF/FVT (88% vs 77%; subgroup P = .0069; risk ratio, 1.19; 95% CI, 1.13-1.27; P < .0001). Pooled thrombosis, infection, leg ischemia, arterial steal, and all-cause mortality rates were 22%, 16%, 10%, 7%, and 17%, respectively. Infection was higher with prosthetic arteriovenous graft than AVF/FVT (19% vs 7%; P = .0054). CONCLUSIONS: Lower-extremity HD access provides a viable salvage option, with preserved secondary patency despite declining intervention-free patency. Autogenous AVF/FVT may provide superior 12-month patency and lower infection risk, although heterogeneity and observational evidence warrant cautious interpretation.
引用
- Alanezi N, Alofisan Y. Outcomes of lower-extremity hemodialysis vascular access: A systematic review and meta-analysis. J Vasc Surg. 2026. PMID: 42754185. doi:10.1016/j.jvs.2026.07.085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。